Roche to Invest $550 Million in U.S. CGM Manufacturing Expansion
Roche has announced a significant investment plan to enhance continuous glucose monitoring (CGM) manufacturing capabilities in the United States over the next five years. According to a report by our sister site, Drug Delivery Business News, the company intends to invest up to $550 million in expanding its Diagnostics facility in Indianapolis.
The investment is likely to enhance domestic production capabilities and reduce reliance on imports. This move could also help mitigate the impact of tariffs imposed during the Trump Administration, thus strengthening local manufacturing infrastructure.
Roche’s CGM technology pipeline includes the Accu-Chek SmartGuide system, which was first unveiled at the 2024 Advanced Technologies & Treatments for Diabetes (ATTD) conference. The company secured CE mark approval for this latest-generation CGM system in July 2024. However, as of now, the Accu-Chek SmartGuide awaits FDA approval.
For more detailed information on this development, readers can visit Drug Delivery Business News, our sister site, which has covered the story in depth.
